Sellas Positive Overall Survival, Response Rate Data in Phase 2 in r/r AML

 - Median Overall Survival (mOS) Not Yet Reached, Now Exceeds 7.7. Months at Latest Follow-Up in the 30 mg BIW Cohort in Patients Relapsed or Refractory to Venetoclax-Based Regimens -

- Overall Response Rate (ORR) of 56% Achieved to Date in Patient with Acute Myeloid Leukemia with Myelodysplasia Related Changes (AML MRC) Prospectively Enrolled in Two Expansion Cohorts; Exceeding Prespecified Target Response Rate of 33% -

https://www.globenewswire.com/news-release/2024/12/09/2993773/0/en/SELLAS-Announces-Positive-Overall-Survival-and-Overall-Response-Rate-Data-from-the-Phase-2-Trial-of-SLS009-in-r-r-AML.html